Form 4: Amgen Executive David M. Reese Reports Acquisition of Stock and Stock Options

EVP & Chief Technology Officer of Amgen, David M. Reese, reports the acquisition of common stock and non-qualified stock options.

Summary

• David M. Reese, EVP & Chief Technology Officer of Amgen, filed a Form 4 detailing changes in beneficial ownership.
• On May 6, 2025, Reese acquired 3,549 shares of common stock and 22,944 non-qualified stock options.
• The common stock was acquired at $0, while the exercise price for the stock options is $270.44.
• The restricted stock units (RSUs) vest in four equal annual installments of 25% each, commencing on May 6, 2026.
• The non-qualified stock options also vest in four equal annual installments of 25% each, commencing on May 6, 2026.
• Following the reported transactions, Reese beneficially owns 42,116 shares of common stock and 22,944 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of shares and options could be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of stock and stock options by an executive could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term incentive plan for the executive, aligning their interests with the company's performance over the next several years.

Industry Context

Executive stock ownership is a common practice in the biotechnology industry to incentivize performance and align management's interests with those of shareholders. This filing reflects standard compensation practices.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are common in the pharmaceutical and biotechnology industries.
• Companies like Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK) also utilize equity-based compensation to incentivize their executives.
• The vesting schedules and terms of these grants are generally in line with industry standards for executive compensation.

Stakeholder Impact

• The acquisition of shares and options by an executive can have a minor positive impact on shareholder sentiment, as it signals confidence in the company's future.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Amgen, AMGN, David M. Reese, Equity Incentive Plan